Emcure Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.38%

Emcure Pharmaceuticals Ltd (EMCURE) has an Asset Resilience Ratio of 1.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Emcure Pharmaceuticals Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

Rs1.29 Billion

≈ $13.98 Million USD Cash + Short-term Investments

Total Assets

Rs93.93 Billion

≈ $1.02 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Emcure Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Emcure Pharmaceuticals Ltd to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Emcure Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Emcure Pharmaceuticals Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs1.29 Billion	1.38%
Total Liquid Assets	Rs1.29 Billion	1.38%

Asset Resilience Insights

Limited Liquidity: Emcure Pharmaceuticals Ltd maintains only 1.38% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Emcure Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Emcure Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Emcure Pharmaceuticals Ltd (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Emcure Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	0.92%	Rs760.43 Million ≈ $8.22 Million	Rs82.33 Billion ≈ $890.34 Million	-2.78pp
2024-03-31	3.70%	Rs2.89 Billion ≈ $31.28 Million	Rs78.06 Billion ≈ $844.21 Million	+0.64pp
2023-03-31	3.06%	Rs2.04 Billion ≈ $22.11 Million	Rs66.73 Billion ≈ $721.61 Million	+0.66pp
2022-03-31	2.40%	Rs1.46 Billion ≈ $15.74 Million	Rs60.63 Billion ≈ $655.74 Million	--

pp = percentage points

About Emcure Pharmaceuticals Ltd

NSE:EMCURE India Drug Manufacturers - Specialty & Generic

Market Cap

$3.56 Billion

Rs328.94 Billion INR

Market Cap Rank

#4519 Global

#191 in India

Share Price

Rs1735.00

Change (1 day)

+1.72%

52-Week Range

Rs1243.10 - Rs1793.20

All Time High

Rs1793.20